|
||
“Change the cancer conversation: The ‘war on cancer’ has run off course,” by Colin Macilwain, Nature. When Angelina Jolie had a double mastectomy in 2013 after genetic tests revealed her susceptibility to certain cancers, she urged others to consider their risk. Even more people will do so now that she has had her ovaries and . . . → Read More: The ‘war on cancer’ has run off course
“Media Coverage of Angelina Jolie’s Choices for Cancer Prevention,” Health News Review. Health News Review evaluates health news using systematic criteria to assess the extent to which a news story uses independent sources, adequately addresses evidence, quantifies harms as well as benefits, identifies conflicts of interest, contributes to disease mongering, establishes the true novelty of . . . → Read More: Media Coverage of Angelina Jolie’s Choices for Cancer Prevention
“Breast Biopsies Leave Room for Doubt, Study Finds,” Denise Grady, The New York Times. New findings reported in JAMA challenge the common belief that a biopsy is the gold standard and will resolve any questions that might arise from an unclear mammogram or ultrasound. In the United States, about 1.6 million women a year . . . → Read More: Breast Biopsies Leave Room for Doubt, Study Finds
“Lost in Transition After Cancer,” Suleika Jaouad, The New York Times Well Blog. Suleika Jaouad writes about the challenges faced by young adults, health, and her experiences with cancer. View the “Life, Interrupted” video series and read previous “Life, Interrupted” columns to learn more about Ms. Jaouad’s experiences. It is hard not to speak . . . → Read More: Lost in Transition After Cancer
“Marketing to Doctors,” John Oliver, Last Week Tonight with John Oliver. This eye-opening video reveals how pharmaceutical companies spend billions of dollars every year marketing drugs to you and your doctors. A study in 2013 found that 9 out of 10 of the top ten drug manufacturers spent more on marketing than they did . . . → Read More: Marketing to Doctors
“Why Drugs Cost So Much,” Peter Bach, The New York Times. ELI LILLY charges more than $13,000 a month for Cyramza, the newest drug to treat stomach cancer. The latest medicine for lung cancer, Novartis’s Zykadia, costs almost $14,000 a month. Amgen’s Blincyto, for leukemia, will cost $64,000 a month. Cyramza costs the average . . . → Read More: Why Drugs Cost So Much
“Doing More for Patients Often Does No Good,” Aaron E. Carroll, The New York Times. Given the remarkable advances that have been made in the last 50 or so years in pharmaceuticals, medical devices and surgical procedures, it’s not a surprise that people want more, and more invasive, care than they have had in the . . . → Read More: Doing More for Patients Often Does No Good
“Shirley Temple Black: She broke the silence about breast cancer,” Peggy Orenstein, The New York Times. In the fall of 1972, Shirley Temple Black noticed a lump in her left breast. Peggy Orenstein writes that it’s hard to imagine now, when celebrity breast-cancer diagnoses bring an inevitable publicity windfall, how risky it was for this . . . → Read More: The Lives They Lived: Shirley Temple Black
“Courageous Nonprofit Leadership Groups Are Greatly Needed,” Pablo Eisenberg, Chronicle of Philanthropy. As the government has shrunk its role, the public expects more of nonprofits, but such groups can’t shoulder that burden unless they have more dollars at their disposal. Most grant makers don’t give more than the 5 percent of assets that is the . . . → Read More: Courageous Nonprofit Leadership Groups Greatly Needed
“Don’t Homogenize Health Care,” Sandeep Jauhar The New York Times. In American medicine today, “variation” has become a dirty word. Variation in the treatment of a medical condition is associated with wastefulness, lack of evidence and even capricious care. To minimize variation, insurers and medical specialty societies have banded together . . . → Read More: Don’t Homogenize Health Care |
||
| Copyright © 2025 Breast Cancer Consortium – Archives - All Rights Reserved. Privacy Policy | ||